Tuesday, July 1, 2025 7/1/2025

Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease

Award Number: R44AG061995
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2024

Group Awards By:

View Award Description

Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease - Vivreon Biosciences, LLC 4940 Carroll Canyon Rd. Suite 110 San Diego, CA 92121 milton@vivreonbiosciences.com Vivreon Biosciences – NIA SBIR #PA-20-272 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements; Notice of Special Interest (NOSI): Administrative Supplement for Providing Technical and Business Assistance (TABA) Funding to SBIR/STTR Awardees (Admin Supp) Notice Number: NOT-OD-21- 062 Project Summary Vivreon Biosciences is pleased to apply for NIA SBIR Supplement #PA-20-272 to develop intellectual property protection for the preclinical candidate in our currently funded SBIR R44AG061995, “Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease”. Supplemental funding is urgently required for intellectual property freedom-to-operate (FTO) analysis and patent filings. The programmatic goal of R44AG061995 is to de-risk our novel Alzheimer’s therapeutic development candidate to make this program an attractive investment opportunity for third-party investors and pharmaceutical partners. To arrive at a highly promising patentable development candidate, our workflow involved rigorous lead optimization and candidate selection studies. Vivreon medicinal chemists designed and synthesized new chemical entities (NCEs) with calculated parameters suitable for a CNS drug, which were then tested in potency, ADME, and DMPK assays. These efforts have yielded a candidate therapeutic that demonstrates drug-like properties appropriate for further development. The Vivreon candidate therapeutic is orally bioavailable, highly brain penetrant, and effective in mouse and human models of AD. TABA supplemental funding is urgently required for technical and business services to support intellectual property protections.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $1,273,378 )
2023	2023	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Aging Research	000	3	5/15/2023	NON-COMPETING CONTINUATION	$1,223,378
2023	2023	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Aging Research	001	3	7/28/2023	SUPPLEMENT FOR EXPANSION	$50,000
														Subtotal = $1,273,378

Issue Date FY: 2022 ( Subtotal = $1,276,596 )
2022	2022	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Aging Research	000	2	9/14/2022	COMPETING CONTINUATION	$1,276,596
														Subtotal = $1,276,596

Grand Total All Awards = $2,549,974

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease

Award Number: R44AG061995

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer